Log In
BCIQ
Print this Print this
 

Novexatin (NP213)

  Manage Alerts
Collapse Summary General Information
Company NovaBiotics Ltd.
DescriptionCyclic cationic membranolytic peptide
Molecular Target
Mechanism of Action 
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationOnychomycosis
Indication DetailsTreat fungal nail infection
Regulatory Designation
PartnerTaro Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/02/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today